These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24751697)

  • 1. Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8.
    Michalk I; Feldmann A; Koristka S; Arndt C; Cartellieri M; Ehninger A; Ehninger G; Bachmann MP
    PLoS One; 2014; 9(4):e95517. PubMed ID: 24751697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
    Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
    J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
    Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
    Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
    Haagen IA; de Lau WB; Bast BJ; Geerars AJ; Clark MR; de Gast BC
    Cancer Immunol Immunother; 1994 Dec; 39(6):391-6. PubMed ID: 7528094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
    Aschmoneit N; Steinlein S; Kühl L; Seifert O; Kontermann RE
    Sci Rep; 2021 Jul; 11(1):13880. PubMed ID: 34230555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
    Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterodimeric complex formation with CD8 and TCR by bispecific antibody sustains paracrine IL-2-dependent growth of CD3+ CD8+ T cells.
    De Lau WB; Boom SE; Heije K; Griffioen AW; Braakman E; Bolhuis RL; Tax WJ; Clevers H; Bast BJ
    J Immunol; 1992 Sep; 149(6):1840-6. PubMed ID: 1387662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.
    Smans KA; Hoylaerts MF; De Broe ME
    Cancer Immunol Immunother; 1994 Jan; 38(1):43-52. PubMed ID: 8299118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy.
    Ohta S; Tsukamoto H; Watanabe K; Makino K; Kuge S; Hanai N; Habu S; Nishimura T
    Immunol Lett; 1995 Jan; 44(1):35-40. PubMed ID: 7721341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
    Brandl C; Haas C; d'Argouges S; Fisch T; Kufer P; Brischwein K; Prang N; Bargou R; Suzich J; Baeuerle PA; Hofmeister R
    Cancer Immunol Immunother; 2007 Oct; 56(10):1551-63. PubMed ID: 17310380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
    Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
    MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3.
    Stel AJ; Kroesen BJ; Jacobs S; Groen H; de Leij LF; Kluin-Nelemans HC; Withoff S
    J Immunol; 2004 Nov; 173(10):6009-16. PubMed ID: 15528335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
    Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
    Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
    Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
    BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.